<?xml version="1.0" encoding="UTF-8"?>
<ref id="B155-jcm-09-02084">
 <label>155.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hung</surname>
    <given-names>I.F.N.</given-names>
   </name>
   <name>
    <surname>Lung</surname>
    <given-names>K.C.</given-names>
   </name>
   <name>
    <surname>Tso</surname>
    <given-names>E.Y.K.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Chung</surname>
    <given-names>T.W.H.</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>M.Y.</given-names>
   </name>
   <name>
    <surname>Ng</surname>
    <given-names>Y.Y.</given-names>
   </name>
   <name>
    <surname>Lo</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Tam</surname>
    <given-names>A.R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital with COVID-19: An Open-Label, Randomised, Phase 2 Trial</article-title>
  <source>Lancet</source>
  <year>2020</year>
  <volume>395</volume>
  <fpage>1695</fpage>
  <lpage>1704</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id>
  <pub-id pub-id-type="pmid">32401715</pub-id>
 </element-citation>
</ref>
